Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 3.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 318,820 shares of the medical equipment provider's stock after buying an additional 11,777 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.16% of Zimmer Biomet worth $33,307,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Intech Investment Management LLC grew its position in shares of Zimmer Biomet by 21.3% during the third quarter. Intech Investment Management LLC now owns 2,379 shares of the medical equipment provider's stock worth $257,000 after purchasing an additional 417 shares in the last quarter. FMR LLC grew its holdings in Zimmer Biomet by 27.6% during the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider's stock valued at $80,999,000 after buying an additional 162,384 shares in the last quarter. Brooklyn Investment Group bought a new stake in shares of Zimmer Biomet during the third quarter valued at approximately $35,000. Townsquare Capital LLC purchased a new position in shares of Zimmer Biomet in the third quarter worth $341,000. Finally, Glenmede Trust Co. NA boosted its position in shares of Zimmer Biomet by 163.9% during the third quarter. Glenmede Trust Co. NA now owns 44,554 shares of the medical equipment provider's stock worth $4,810,000 after acquiring an additional 27,673 shares during the last quarter. Institutional investors own 88.89% of the company's stock.

Insider Activity

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.70% of the company's stock.

Remove Ads

Zimmer Biomet Stock Up 0.1 %

Shares of Zimmer Biomet stock traded up $0.11 on Thursday, reaching $112.61. The stock had a trading volume of 537,649 shares, compared to its average volume of 1,824,670. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $22.42 billion, a P/E ratio of 25.31, a P/E/G ratio of 1.95 and a beta of 1.04. The company has a 50 day moving average price of $107.35 and a 200 day moving average price of $107.18. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $130.89.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the firm posted $2.20 earnings per share. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is 21.57%.

Analyst Ratings Changes

ZBH has been the subject of a number of research analyst reports. Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Raymond James lowered their target price on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. Finally, Royal Bank of Canada lowered their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.